ドイツのCOVID-19感染拡大対策製品（COVID-19用医薬品市場、COVID-19用ワクチン市場、個人用保護具 (PPE)、自己採取用スワブ、COVID-19用人工知能 (AI)、個人用防具、遠隔放射線診断、眼球保護具など）市場：2024年まで
Germany COVID-19 Pandemic Mitigation Products (COVID-19 Drugs Market, COVID-19 Vaccine Market, PPE, Self-collection Swabs, COVID-19 AI, Personal Protection Gear, Teleradiology, Eye Protection, and More) Market to 2024
|ドイツのCOVID-19感染拡大対策製品（COVID-19用医薬品市場、COVID-19用ワクチン市場、個人用保護具 (PPE)、自己採取用スワブ、COVID-19用人工知能 (AI)、個人用防具、遠隔放射線診断、眼球保護具など）市場：2024年まで|
発行: Homeland Security Research Corporation (HSRC)
ページ情報: 英文 420 Pages; 220 Tables & Figures
ドイツの新型コロナウイルス感染症 (COVID-19) 感染拡大向け対策製品の市場規模は、2020年～2024年の累計で640～840億米ドルに達する見通しです (年度・予測シナリオに因ります)。
当レポートでは、ドイツ国内のCOVID-19感染拡大対策製品の市場について分析し、全体的な市場規模 (処置件数) の動向見通しや、主要製品／サービス別・エンドユーザー別の詳細動向、シナリオ別の将来予測、業界関係者が今後解決すべき課題、といった情報を取りまとめてお届けいたします。
Germany COVID-19 Pandemic Mitigation Products
(COVID-19 Drugs Market, COVID-19 Vaccine Market, PPE, Self-collection Swabs, COVID-19 AI, Personal Protection Gear, Teleradiology, Eye Protection, CT, X-Ray, Ultrasound, COVID-19 IT, Telemedicine, PACS, Face Shields, PPE Gowns, Coronavirus Homecare, Mechanical Ventilators, Gloves, E-Health, Robotic PCR Market, Point of Care Antigen Test, PCR Reagents, Face Masks, ICU, Contact Tracing, Sterilization Systems, Point of Care Serologic Test, Polymerase Chain Reaction, Test Kits, Surge Hospitals and More) Market to 2024.
On the backdrop of the need for essential medical products and services, a new market has emerged, the COVID-19 pandemic mitigation products market. This Germany COVID-19 pandemic mitigation cumulative 2020-2024 market is worth $64-84 Billion* .
(*) Market size is year and scenario dependent.
To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios:
Angela Merkel, the Chancellor, and a scientist (PhD in Quantum Chemistry) is considered by the majority of the Germans to be the ideal leader for the COVID-19 crisis.
If one big democratic country can be considered to have a "decent" COVID-19 disaster management, it is Germany. Fatalities are fewer than in other countries, the government supports suffering firms, politicians & workers are competent.
Germany used its nationwide network of more than 190 testing laboratories that ramped up its testing capability, before the federal government knew a pandemic was around the corner. Germany conducted 350,000 tests a week and can do many more tests.
As the federal government hesitated, local governments reacted promptly to close down public places and trace COVID-19 infected contacts. Germany was fortunate, as it got an "early warning" from Italy. Germany used the lead time to knock down the pandemic curve.
German enacted prevention protocols in place facilitated the country's response to the outbreak. These protocols included early establishment of testing capacities, high levels of testing and an efficient suppression strategy amongst elder population and cost-effective use of Germany's abundant 660,000 hospital beds.
Exploiting its early accomplishment in segregating the infected, Germany moved to the second phase of the coronavirus pandemic mitigation, tracking each chain of the virus. It established a capacity of more than 4 million tests a week and contact tracing by thousands of "containment scouts" at Germany's public-health organizations.
To protect workers' income, Germany has ramped up Kurzarbeitergeld (Salary for temporary work), an instituted system under which the government covers up to 86% of the missed earnings of workers. While the German vehicle industry ceased production for a while, other industry segments like pharma and petrochemicals kept working.
The IMF forecasts a 7% contraction by 2020, graver than the 2008-2009 crisis. Germany's accomplishments in coping with the coronavirus are indisputable.
This 420 -page market report is the most comprehensive review of the German COVID-19 market available today. The objective of this report is to provide today's strategic decision-makers with an expert 360-degree, time-sensitive, detailed view of this interconnected market.
The ‘Germany COVID-19 Pandemic Mitigation Products Market - 2020-2024 ’ report presents a thorough market analysis of 29 products & services, 6 end user, 4 revenue source markets. Furthermore, the report provides updated extensive data of 37 key vendors.
(including companies' profile, recent annual revenues, COVID-19 mitigation activities & products and contact information).
Moderna, IBM, 3M Company, Philips NV, Johnson & Johnson, Roche, Nvidia Corporation, Thermo Fisher Scientific, Siemens, Toshiba, Google, Samsung Electronics Co, GE Healthcare, Medtronic, MedWhat, MedyMatch, Merck, Metabiota, Micron Technology, Infermedica, Infervision, Inovio Pharmaceuticals, Microsoft Corporation, Mindshare Medical, Morpheo, Pfizer, Philips NV, Maxim Biotech, Honeywell Safety Products, Philips Healthcare, Siemens, Recursion Pharmaceuticals, Fujifilm Holdings Corporation, 3Scan, Abbott , AbCellera, Advenio Technosys, Agfa Healthcare, Agilent Technologies, AiCure, Aindra, Allscripts Healthcare Solutions, Amara Health Analytics, Amazon , analyticsMD, Apixio, Apple, Arterys Inc., Atlas Wearables, Atomwise, Avalon Nutrition VITL, Babylon Health, Bay Labs, Behold.ai, benevolent.ai, BIOBEATS, BlueDot, Bollé Safety, Bullard, Buoy Health, Care Angel Wearables QorQL, Careskore, Clinithink, Cloud Pharmaceuticals, CloudMedx, CureMetrix Mental health Ginger.io, Cyrcadia, Deep 6 AI, Deep Genomics, Dell Technologies Inc., Delta Plus Group, Desktop Genetics Virtual mate Ada Health, DreaMed Diabetes, Dupont, EaglEyeMed, Eli Lilly, Encon Safety Products, Enlitic, EnsoData, Entopsis, Envisagenics Research iCarbonX, ERB Industries Inc., Ergodyne, Essilor of America, Flashback Technologies, Flow Health, Ford, Freenome, Frequency Therapeutics Inc., Gateway Safety Inc., General Motors, General Vision, Gentex Corporation, Gibco, Gilead Sciences, Globavir Biosciences, Healint, Health Fidelity, HealthNextGen, HexArmor, Hindsait, Imagen Technologies, Imagia Cybernetics, Inside DNA, InSilico Medicine, Intel Corporation, Intendu, Invitrogen, Ion Torrent, Ironwear, Jvion, Kapa Biosystems, Keen Eye Technologies, Kimberly-Clark Professional, Lexmark International Inc., LifeGraph, Lucina Health, Lumiata, Lunit, Lytics, Magnea, Maxwell MRI, McKesson Corporation, MCR Safety, Medal, Medalogix, Medasense, MedAware, Niramai Health Analytix, Novarad Corporation, NuMedii, Numerate, Nuritas Pharma Turbine, Oncora Medical, Ovuline, PeerWell, PhysIQ, Precision Health Intelligence, Predible Health, Profility, Proscia, pulseData, Pyramex Safety, Qualaris Healthcare Solutions, Qualcomm Incorporated, Qualcomm Incorporated, Qure.Ai, Radians Inc., Roam Analytics, RxPREDICT, Safety Optical Service Ltd, Sanofi, Saykara, Sellstrom Manufacturing Company (SureWerx), Sense.ly, Sensory Inc., Sigma-Aldrich Corp., Skymind Inc., Vir Biotechnology Inc., VisionAid Inc., WuXi Biologics, Xilinx Inc. and more.
The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen identification, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, ultrasound, electron microscopy, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.
As early as January 20, 2020 we recruited all our analysts to research the COVID-19 pandemic mitigation related products purchases. We interviewed hundreds of experts, participated in more than 95 conferences and webinars, reviewed more than 1,500 publications and interviewed executives of more than 65 pandemic related companies.